Stuttgart - Delayed Quote EUR

Wave Life Sciences Ltd. (1U5.SG)

11.10

-0.40

(-3.48%)

At close: January 31 at 9:34:15 PM GMT+1

Is Wave Life Sciences (WVE) the Top Small Cap Stock to Buy with the Highest Upside Potential?

We recently published a list of the Top 10 Small Cap Stocks to Buy with the Highest Upside Potential. In this article, we are going to take a look at where Wave Life Sciences Ltd. (NASDAQ:WVE) stands against other top small cap stocks to buy with the highest upside potential. What Would 2025 Look Like […]

Insider Monkey 18 days ago

WVE
Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation

Entering 2025 having demonstrated rapid translation of genetic insights to positive clinical data; advancing clinically validated and multi-modal pipeline with the potential to treat well over 100 million patients CTAs submitted for Phase 1 INLIGHT clinical trial of WVE-007, a novel, long-acting, muscle-sparing GalNAc-siRNA approach for obesity targeting INHBE grounded in human genetics; proof-of-concept clinical data expected in 2025 Pioneering entirely new therapeutic field of RNA editing and

GlobeNewswire 18 days ago

WVE
Is Wave Life Sciences Ltd. (WVE) the Best Growth Stock to Buy Now Under $25?

We recently compiled a list of the 12 Best Growth Stocks Under $25 to Buy Now. In this article, we are going to take a look at where Wave Life Sciences Ltd. (NASDAQ:WVE) stands against the other growth stocks. AI is the Most Defining Theme of 2025, Says Expert Most experts agree that the AI wave […]

Insider Monkey 22 days ago

WVE
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twice-annual administration WVE-007 is Wave’s first siRNA program to enter clinical development and uses best-in-class oligonucleotide chemistry and GalNAc delivery Wave expects to initiate the first-in-human study of WVE-007 in 1Q 2025 CAMBRIDGE, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Wave Life Scien

GlobeNewswire last month

WVE
Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 9:45 a.m. PT / 12:45 p.m. ET. A live webcast of this presentation can be a

GlobeNewswire last month

WVE
Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in December. 7ᵗʰ Annual Evercore HealthCONx ConferenceDate: Tuesday, December 3, 2024Analyst-led fireside chat: 3:00 p.m. ET Citi 2024 Glob

GlobeNewswire 2 months ago

WVE
Wave Life Sciences to Present at Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:30 p.m. GMT / 11:30 a.m. ET. A live webcast of this presenta

GlobeNewswire 2 months ago

WVE
Wave Life Sciences Ltd. (NASDAQ:WVE) Released Earnings Last Week And Analysts Lifted Their Price Target To US$22.20

Wave Life Sciences Ltd. ( NASDAQ:WVE ) missed earnings with its latest third-quarter results, disappointing...

Simply Wall St. 2 months ago

WVE
Wave Life Sciences Third Quarter 2024 Earnings: Misses Expectations

Wave Life Sciences ( NASDAQ:WVE ) Third Quarter 2024 Results Key Financial Results Net loss: US$61.8m (down from...

Simply Wall St. 2 months ago

WVE
WAVE Life Sciences Ltd (WVE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

Despite a net loss, WAVE Life Sciences Ltd (WVE) showcases promising clinical progress and a strengthened financial position to support future growth.

GuruFocus.com 2 months ago

WVE
Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -67.86% and 149.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

WVE
Wave Life Sciences: Q3 Earnings Snapshot

SINGAPORE (AP) — Wave Life Sciences Pte. Ltd. (WVE) on Tuesday reported a loss of $61.8 million in its third quarter. On a per-share basis, the Singapore-based company said it had a loss of 47 cents.

Associated Press Finance 2 months ago

WVE
Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced three wholly owned GalNAc-AIMer preclinical programs that offer first-in-class approaches to address unmet needs in cardiometabolic diseases WVE-007 (INHBE GalNAc-siRNA) clinical trial on track for 1Q 2025; preclinical data demonstrates opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following

GlobeNewswire 2 months ago

WVE
Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?

Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

WVE

YMAB
Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, November 12, 2024, to review the company’s third quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the investors section

GlobeNewswire 2 months ago

WVE
Institutional investors in Wave Life Sciences Ltd. (NASDAQ:WVE) see US$94m decrease in market cap last week, although long-term gains have benefitted them.

Key Insights Significantly high institutional ownership implies Wave Life Sciences' stock price is sensitive to their...

Simply Wall St. 2 months ago

WVE
Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for WVE-007 demonstrate opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s Recent proof-of-mechanism data for WVE-006 unlocked Wave’s best-in-class RNA editing capabilities; three new wholly owned RNA editing programs targeting PNPLA3, LDLR and APOB are first-in-class approaches to address si

GlobeNewswire 3 months ago

WVE
How to play biotech stocks: Insmed and Wave Life Sciences

There are opportunities for investors in the healthcare sector, but it lies with the small-cap biotech companies, not big pharma, Stacey Sears, the Emerald Growth Fund (HSPGX) portfolio manager at Emerald Advisers, says. Sears sits down with Julie Hyman and Josh Lipton on Market Domination to discuss how to play biotech stocks. “If you think about advancements in DNA editing, advancements in RNA editing, which are ongoing as we sit here today, and broader pursuit of orphan and rare diseases. Decoding of the genome has really enabled that, and small caps have been a big player in that. As a matter of fact, if you take a look at 2023, approximately two-thirds of clinical trials were started by companies in the small and emerging biotechnology space, and approximately 56% of the new drug substances approved in 2023 originated within small and emerging biotechnology companies,” Sears tells Yahoo Finance. The portfolio manager explains, “Valuation has always been more challenging within the healthcare area, but I would say what is now a tailwind is that the sector has been underperforming over the last couple of years," given its inverse performance with interest rates. Sears highlights Insmed (INSM) and Wave Life Sciences (WVE) as small-cap biotech names that are poised to gain. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Naomi Buchanan.

Yahoo Finance Video 3 months ago

WVE

INSM
Wall Street Analysts Predict a 34.53% Upside in Wave Life Sciences (WVE): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Wave Life Sciences (WVE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 3 months ago

WVE
1 Brand-New Big Reason to Buy This Biotech Stock Right Now

This stock currently has a good balance of risk and potential rewards.

Motley Fool 3 months ago

WVE

Performance Overview

Return	1U5.SG	S&P 500
YTD	-9.02%	+2.26%
1-Year	+176.12%	+22.65%
3-Year	+522.90%	+36.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Wave Life Sciences Ltd. (1U5.SG)

Is Wave Life Sciences (WVE) the Top Small Cap Stock to Buy with the Highest Upside Potential?

Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation

Is Wave Life Sciences Ltd. (WVE) the Best Growth Stock to Buy Now Under $25?

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Wave Life Sciences to Present at Upcoming Investor Conferences

Wave Life Sciences to Present at Jefferies London Healthcare Conference

Wave Life Sciences Ltd. (NASDAQ:WVE) Released Earnings Last Week And Analysts Lifted Their Price Target To US$22.20

Wave Life Sciences Third Quarter 2024 Earnings: Misses Expectations

WAVE Life Sciences Ltd (WVE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates

Wave Life Sciences: Q3 Earnings Snapshot

Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?

Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024

Institutional investors in Wave Life Sciences Ltd. (NASDAQ:WVE) see US$94m decrease in market cap last week, although long-term gains have benefitted them.

Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

How to play biotech stocks: Insmed and Wave Life Sciences

Wall Street Analysts Predict a 34.53% Upside in Wave Life Sciences (WVE): Here's What You Should Know

1 Brand-New Big Reason to Buy This Biotech Stock Right Now

Performance Overview